Summary
In light of the growing interest in drug-value assessment agencies in the Administration and Congress, the Wynne Health Group presents a side-by-side of the most relevant health-technology assessment (HTA) models and proposed policies.
While H.R. 3 negotiations relies on international reference prices to set an upper payment limit, Senate Finance Chair Ron Wyden (D-OR) has expressed interest in substituting domestic reference prices in lieu of international reference pricing and separately developing an entity to appraise drug values to assist negotiators. President Biden has also previously commented on the use an “independent drug value assessment agency,” similar to that of Germany, during his campaign.
It is becoming a growing possibility that such an entity could be included in either a forthcoming budget reconciliation package or the executive order-driven Department of Health and Human Services (HHS) plan to combat excessive pricing of prescription drugs. The attached chart examines the methodology and applicability of the following HTA models:
- The Institute of Clinical and Economic Review (ICER);
- The USC Schafer Center and the Aspen Institute’s Institute for Health Technology Assessment (IHTA); and
- Germany’s Institute for Quality and Efficiency in Health Care (IQWiG).